Allergan Inc. (AGN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.6%. By the end of trading, Allergan rose $0.90 (1.0%) to $88.83 on light volume. Throughout the day, 1,311,512 shares of Allergan exchanged hands as compared to its average daily volume of 2,721,600 shares. The stock ranged in a price between $87.64-$89.20 after having opened the day at $87.64 as compared to the previous trading day's close of $87.93. Other companies within the Health Care sector that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 13.6%, Bovie Medical Corporation ( BVX), up 11.9%, Arrhythmia Research Technology ( HRT), up 11.7% and Genvec ( GNVC), up 11.1%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $26.2 billion and is part of the drugs industry. Shares are down 4.1% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, GTx ( GTXI), down 65.5%, Mast Therapeutics ( MSTX), down 43.4%, Epizyme ( EPZM), down 14.1% and Stereotaxis ( STXS), down 12.7% , were all laggards within the health care sector with Valeant Pharmaceuticals International ( VRX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget